First oral once-daily complement Factor B inhibitor approved in China, now racing to file a U.S. IND — thesis turns on whether ex-China data can anchor an FDA path

Bull

FDA accepts the pre-IND package and provides a clear, manageable pathway — ideally confirming that the Chinese Phase 3 data (59.5% response in treatment-naive PNH vs. eculizumab 8.3%; 52.8% in C5 inhibitor-failed PNH) can anchor U.S. development with a targeted bridging study rather than a full de novo trial. A clean IND submission would validate the ex-China licensing thesis, de-risk the $1.4B milestone structure with Haisco, and position ciprocopan as a credible oral once-daily entrant in the U.S. PNH market.

Bear

FDA raises concerns about the acceptability of China-only trial data — citing patient population differences, site quality, or non-alignment with U.S. regulatory standards — and requires a large, fully powered U.S. or global pivotal trial before approval can be considered. Additional failure modes include FDA requesting a different primary endpoint than used in China or declining to accept the single-arm C5 inhibitor-failed study design, materially extending timelines and capital requirements beyond the current cash runway into 1H 2029.